Apixaban Significantly Reduces VTE in Cancer Patients Apixaban Significantly Reduces VTE in Cancer Patients
Cancer patients at risk for venous thromboembolism significantly benefited from apixaban compared with placebo. But routine primary thromboprophylaxis is not yet recommended.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

J & J ’s Cerenovus launches global thrombectomy registry
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus said today that it launched a new registry aiming to collect and analyze stroke-inducing blood clots removed with the company’s Embotrap II revascularization device. The Irvine, Calif.-based company touted the Excellent registry as the single largest global registry of its kind to date, looking to enroll up to 1,000 ischemic stroke patients across 50 locations in the U.S. and Europe. Investigators in the trial will collect and analyze clots removed to explore how different characteristics, including size, composition and density may affect outcomes, the com...
Source: Mass Device - December 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Featured Neurological cerenovus johnsonandjohnson Source Type: news

AHA Scientific Statement: Low Risk of Side Effects for Statins
MONDAY, Dec. 10, 2018 -- Statins are associated with a low risk for side effects, according to a scientific statement from the American Heart Association (AHA) published online Dec. 10 in Arteriosclerosis, Thrombosis and Vascular Biology. Connie B.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 10, 2018 Category: Pharmaceuticals Source Type: news

ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
WEDNESDAY, Dec. 5, 2018 -- Rivaroxaban can prevent venous thromboembolism (VTE) in cancer patients at increased risk, according to a study presented at the annual meeting of the American Society of Hematology, held from Dec. 1 to 4 in San... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Cerebral Venous Sinus Thrombosis Misdiagnosed As Migraine Cerebral Venous Sinus Thrombosis Misdiagnosed As Migraine
A misdiagnosis of cerebral venous thrombosis resulted in a catastrophic outcome for this patient. What were the potentially avoidable pitfalls in this case?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

' Marginal Benefit' With Rivaroxaban in Cancer Patients'Marginal Benefit' With Rivaroxaban in Cancer Patients
The oral drug rivaroxaban was used for prophylaxis against primary venous thromboembolism in ambulatory cancer patients treated in the outpatient setting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Phase 3 CASSINI Data Presented on the Use of XARELTO ® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Inflammation, VTE, and What We Can Do About It Inflammation, VTE, and What We Can Do About It
A new study examines the association between venous thromboembolism and three chronic inflammatory diseases. How might anti-inflammatory treatments impact the risk of VTE in these patients?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Drug dramatically reduces risk of dangerous blood clots in cancer patients
(The Ottawa Hospital) A large clinical trial published in the New England Journal of Medicine provides the first approach for safely preventing blood clots (venous thromboembolism) in people with cancer. Venous thromboembolism is the second leading cause of death in cancer patients and it can also affect quality of life. About half of people newly diagnosed with a solid cancer could be candidates for the strategy, which involves a low dose of a direct oral anticoagulant called apixaban. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

Cleveland Clinic-led study: Rivaroxaban reduced blood clots and related death in cancer patients
(Cleveland Clinic) Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly reduced VTE and VTE-related death for outpatient, at-risk cancer patients while they were taking the oral blood thinner. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

Risk of VTE During and After Hospitalization in IBD Patients Risk of VTE During and After Hospitalization in IBD Patients
Venous thromboembolism is a recognized complication of inflammatory bowel diseases. When are IBD patients at most risk of thromboembolic events?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

ECG Educational Standards for Prehospital Providers
The level of knowledge pertaining to electrocardiogram (ECG) interpretation among prehospital healthcare providers undoubtedly impacts patient outcomes. EMS personnel from EMRs to EMTs, AEMTs and paramedics play a critical role in the care of acutely ill and injured patients. First responders make critical decisions regarding initial assessment, intervention and transport. They must do so expeditiously. Such decisions have profound implications on quality and continuity of care. The importance of such actions becomes especially evident in regard to on-scene ECG interpretation. The prehospital providers' ECG interpretation ...
Source: JEMS Patient Care - November 27, 2018 Category: Emergency Medicine Authors: Jonathan Barney, BA, EMT, MS3 Tags: Training Exclusive Articles Cardiac & Resuscitation Source Type: news

Recommended Therapies for Polycythemia Vera Underused
Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 27, 2018 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Recommended Therapies for Polycythemia Vera Underused
TUESDAY, Nov. 27, 2018 -- Among older patients with polycythemia vera (PV), therapeutic phlebotomy and hydroxyurea (HU) are associated with improved overall survival and decreased risk for thrombosis but are underused, according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 27, 2018 Category: Pharmaceuticals Source Type: news

ASH releases new clinical practice guidelines for venous thromboembolism
(American Society of Hematology) Venous thromboembolism (VTE), a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death. Despite effective new options for prevention and treatment, VTE remains a threat underappreciated by the general public, causing up to 100,000 deaths annually in the United States alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 27, 2018 Category: International Medicine & Public Health Source Type: news

Reduce your risk of deep vein thrombosis with two natural extracts
(Natural News) Sitting in place for hours on end can make you prone to a life-threatening condition called deep vein thrombosis. In an article in Natural Health 365, researchers reveal that the French maritime pine and nattokinase can prevent its onset. These two natural substances are able to break apart blood clots before the latter become... (Source: NaturalNews.com)
Source: NaturalNews.com - November 21, 2018 Category: Consumer Health News Source Type: news

Hancock Jaffe clears Colombian regulatory hurdle for VenoValve trial
Hancock Jaffe Laboratories (NSDQ:HJLI) said today that Colombia’s INVIMA, the country’s FDA equivalent, completed their review of the company’s application for a first-in-human trial of its VenoValve, clearing another hurdle towards launching the study. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis. The Irvine, Calif.-based company said that the next step is to present an official application for approval of the trial from INVIMA’s Medica...
Source: Mass Device - November 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular hancockjaffelabs Source Type: news

Boston Sci Puts up $4B for BTG
Boston Scientific is back on the M&A trail. This time the Marlborough, MA-based company is offering $4 billion to acquire BTG in a deal set to close in the first half of 2019. London-based BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere Y-90 radiotherapy microspheres and the GALIL cryoablation system, used to treat patients with liver, kidney and other cancers. BTG’s Interventional Medicine business also has a highly-differentiate...
Source: MDDI - November 20, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Migraines Mimicking Stroke Still Pose Diagnostic Challenges
(MedPage Today) -- Migraine with aura responsible for 18% of improper thrombolytic treatments (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 19, 2018 Category: Neurology Source Type: news

Patient Education Ups VTE Prophylaxis in Hospital Setting
MONDAY, Nov. 19, 2018 -- A patient-centered education bundle intervention can reduce nonadministration of venous thromboembolism (VTE) prophylaxis, according to a study published online Nov. 16 in JAMA Network Open. Elliott R. Haut, M.D., Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news

BTG Rides High on 2-Year Sentry Data at VIVA
Two-year results from BTG’s SENTRY trial paint a positive picture of the company’s bioconvertible inferior vena cava (IVC) filter. The London-based company unveiled the data at the Vascular Intervention Advances conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, found that in addition to providing protection against pulmonary embolism (PE) during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolization through two years of imaging-intensive follow-up. In the long-term data, 85 patients were followed for 24 ...
Source: MDDI - November 9, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

New magnetically controlled thrombolytic successfully passed preclinical testing
(ITMO University) New anti-thrombosis drug based on magnetite nanoparticles developed at ITMO University was successfully tested on animals. Preclinical studies showed drug's high efficacy and safety. Clot dissolution time of the new drug is 20 times shorter than the one of traditional medications. The range of permissible concentrations is very high, and the minimum dose of the active substance was a hundred times smaller than usual. The results are published in Applied Materials and Interfaces. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2018 Category: International Medicine & Public Health Source Type: news

Make the Diagnosis: No Spiders in this Web
(MedPage Today) -- A 72-year-old woman went to her doctor complaining of multiple skin lesions on her lower legs for several months. The lesions would appear in a net-like pattern, become painful ulcerations, and then leave atrophic scars. She was concerned about the lesions because she had already had several bouts of deep vein thrombosis. Can you diagnose the patient? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 29, 2018 Category: Cardiology Source Type: news

Abbott & #039;s HeartMate 3 Pump Can Now be Offered as a Destination Therapy
As if Abbott Laboratories hasn't had enough to celebrate this year, the company just scored FDA approval for the use of its Heartmate 3 pump as a destination therapy. The approval, which CEO Miles White hinted about earlier in the week, is a big win for Abbott – and an even bigger win for advanced heart failure patients. The approval means that doctors can now offer the HeartMate 3 system to patients who are not eligible for a transplant. These patients will live with the device for the rest of their lives. For advanced heart failure patients who can no longer rely on earlier stage treatment o...
Source: MDDI - October 19, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Business Source Type: news

Aspirin, Anticoagulants Similarly Prevent VTE After TKA
In patients having total knee arthroplasty, aspirin non - inferior for venous thromboembolism, death (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 19, 2018 Category: Cancer & Oncology Tags: Cardiology, Oncology, Orthopedics, Pharmacy, Surgery, Journal, Source Type: news

FDA approves Abbott ’ s HeartMate 3 as a destination therapy
Abbott (NYSE:ABT) said today it won FDA approval for its HeartMate 3 left ventricular assist device, now approved as a destination therapy for patients with advanced heart failure. With the approval, the Chicago-based company said that the device can now be used in patients not eligible for a transplant as a life-long implant. “We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes. The unique design of the HeartMate 3 LVAD—with its Full MagLev technology—takes an established innovation and improves upon it in meaningful ways to help people with...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

Aspirin, Anticoagulants Similarly Prevent VTE After TKA
FRIDAY, Oct. 19, 2018 -- Among patients undergoing total knee arthroplasty (TKA), aspirin alone may provide protection against postoperative venous thromboembolism (VTE) that is similar to that of other anticoagulants, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2018 Category: Pharmaceuticals Source Type: news

What & #039;s Next for Bioresorbable Scaffolds?
Even with new data, the future of bioresorbable scaffolds remains in flux. At TCT 2018 in September, Reva Medical and Abbott Laboratories painted differing pictures with their respective bioresorbable scaffold studies. What now? Dr. Lukasz Koltowski from the Medical University of Warsaw in Warsaw, Poland, presented new data from Reva Medical's "Fantom STEMI" pilot study. The study showed procedural success and clinical utility of the Fantom bioresorbable scaffold in nine patients with acute ST-segment elevated myocardial infarction (“STEMI”) heart attacks. "Many heart atta...
Source: MDDI - October 16, 2018 Category: Medical Devices Authors: Heather R. Johnson Tags: Business Cardiovascular Source Type: news

Prevention of venous thromboembolic complications in firearm injury - Nikolaev KN, Zubritsky VF, Koltovich AP, Vardanyan AV, Kapustin SI, Dolidze DD, Vardanyan VA.
Prevention of venous thromboembolic complications in wounded is a complex problem which has not yet been fully resolved throughout the world. Current state of venous thrombosis prevention in wounded in different countries and certain ways of its improvemen... (Source: SafetyLit)
Source: SafetyLit - October 15, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Rwanda:Rwandan Activist to Be Feted On World Thrombosis Day
[New Times] Christine Ashimwe, the founder of Rwanda Clot Awareness Network, has received a prestigious award for thrombosis advocacy achievements by the International Society on Thrombosis and Haemotasis (ISTH). (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 12, 2018 Category: African Health Source Type: news

Residual Vein Obstruction Down With Compression After DVT
RVO less likely for those receiving compression within 24 hours of diagnosis of deep vein thrombosis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 4, 2018 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pulmonology, Journal, Source Type: news

Residual Vein Obstruction Down With Compression After DVT
THURSDAY, Oct. 4, 2018 -- The likelihood of residual vein obstruction (RVO) is reduced with immediate compression after diagnosis of deep vein thrombosis, according to a study published online Sept. 24 in Blood. Elham E. Amin, from Maastricht... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2018 Category: Pharmaceuticals Source Type: news

Risk of Venous Thromboembolism Recurrence High
At 6 months, rates for provoked, unprovoked, cancer - related VTE are 6.8, 6.92, 9.06 per 100 person - years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 1, 2018 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, Internal Medicine, Critical Care, Nephrology, Neurology, Oncology, Orthopedics, Pharmacy, Pulmonology, Rheumatology, Surgery, Journal, Source Type: news

Anticoagulation for people with cancer and central venous catheters
This review found moderate-certainty evidence that LMWH reduces catheter ‐related venous thromboembolism (CR-VTE); evidence was inconclusive for LMWH effects on mortality and effects of vitamin K antagonists (VKA) on mortality or CR-VTE, and for LMWH versus VKA. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 28, 2018 Category: Consumer Health News Source Type: news

Venous Thromboembolism: Very Troubling Events Venous Thromboembolism: Very Troubling Events
Find out what nurses need to know about the risk assessment, prevention, and treatment of this potentially deadly condition.American Nurse Today (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2018 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

TCT: Lab Study Questions Washing Protocols for Bioprosthetic Heart Valves
(MedPage Today) -- Suggests increased leaflet thrombosis risk when storage solutions are rinsed away pre-implant (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 26, 2018 Category: Urology & Nephrology Source Type: news

Are You Tall? Better Watch Out For Varicose Veins
(CNN) — In what researchers are calling “the largest genetic study ever performed” on varicose vein disease, a Stanford University School of Medicine study found a person’s height to be a significant risk factor for developing varicose veins. “We not only found an association between height and varicose veins, but the genetic studies we did showed a causal link,” said cardiologist and study author Dr. Nicholas Leeper, an associate professor of surgery and cardiovascular medicine at Stanford. “That suggests that the genes and pathways that drive human height are also likely to be ca...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 24, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Local TV Varicose Veins Source Type: news

What Causes Hyperkalemia?
Discussion Potassium (K+) is an alkali metal (Group 1 of periodic table with Hydrogen, Lithium and Sodium) with an anatomic number of 19. Its chemical symbol K, comes from the medieval Latin, kalium which means potash (mainly potassium carbonate or potassium hydroxide), the substance it was first isolated from. Potassium is an important cation and it mainly resides in the intracellular fluid with only a small amount in the extracellular fluid. Potassium regulates cell volume, pH and enzyme functions. Hyperkalemia is defined as a potassium level> 5.5 mEq/L in children and> 6.0 mEq/L in newborns. Hyperkalemia incre...
Source: PediatricEducation.org - September 24, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

' Ridiculous' (in a Good Way) Results With Novel Stent'Ridiculous' (in a Good Way) Results With Novel Stent
Both BIONYX and SORT OUT IX trials showed Resolute Onyx and BioFreedom stents noninferior to the Orsiro device, but stent thrombosis with Resolute Onyx was called'ridiculously low'by one commentator.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

No Clear Benefit for Rivaroxaban After Hospital Discharge
WEDNESDAY, Sept. 19, 2018 -- Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept. 20 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 19, 2018 Category: Pharmaceuticals Source Type: news

DVT (Deep Vein Thrombosis) During Pregnancy
Title: DVT (Deep Vein Thrombosis) During PregnancyCategory: Diseases and ConditionsCreated: 9/18/2018 12:00:00 AMLast Editorial Review: 9/18/2018 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 18, 2018 Category: Cardiology Source Type: news

Antimicrobial lock solutions for preventing catheterrelated infections in haemodialysis
This systematic review of 39 studies (n=4216) found antibiotic antimicrobial and combined (antibiotic ‐non antibiotic) lock solutions (LSs) decreased incidence of catheter‐related infection compared to control LSs. The effect on thrombosis incidence is uncertain for all antimicrobial LSs. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 12, 2018 Category: Consumer Health News Source Type: news

ME & MY OPERATION: New procedure to give you perfect pins after a painful blood clot
60,000 people a year develop a deep vein thrombosis - and Wendy Yaxley, 53, from Lincoln, was one of them. This is her story of pioneering new treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - September 10, 2018 Category: Consumer Health News Source Type: news

Medtronic launches one-month DAPT study for drug-eluting stent in U.S., Japan
Medtronic (NYSE:MDT) said today that it’s launching a study in the U.S. and Japan to evaluate dual antiplatelet therapy in high bleeding risk patients implanted with the Resolute Onyx drug-eluting stent during percutaneous coronary intervention. The company’s Onyx One Clear study is one of the first designed to assess the risk of cardiac death and stent thrombosis following DAPT interruption or discontinuation after one month with a next-gen drug-eluting stent, according to Medtronic. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic launches one-month DAPT study for dr...
Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Medtronic Source Type: news

Medical News Today: Why does olive oil keep heart attack and stroke at bay?
A new study shows that the protein ApoA-IV, which rises in the blood after eating (especially unsaturated fats), prevents thrombosis by blocking platelets. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 7, 2018 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

How olive oil and sleep could stave off heart attacks and strokes: New study examines plasma protein’s role
Apolipoprotein A-IV linked with thrombosis in new study (Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - September 6, 2018 Category: Hospital Management Tags: Hospital News Source Type: news

An Allergy to Red Meat May Be Tied to Heart Disease
FRIDAY, Aug. 31, 2018 -- An allergen in red meat may be tied to heart disease, according to a study published in the July issue of Arteriosclerosis, Thrombosis, and Vascular Biology. Jeffrey M. Wilson, M.D., Ph.D., from the University of Virginia in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2018 Category: Pharmaceuticals Source Type: news

No Reduction in VTE, Death With Rivaroxaban Post-Discharge No Reduction in VTE, Death With Rivaroxaban Post-Discharge
MARINER trial results showed no benefit in reducing a composite of symptomatic venous thromboembolism and death after discharge in high-risk hospitalized patients, although bleeding risk was also low.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Airplane-induced blood clots are more common than you think: Know the signs and what you can do to prevent them
(Natural News) While air travel has made many an advancement in the past decades, it’s still not completely safe. One major risk long-distance flyers take when airborne is blood clots, specifically, a type of blood clot known as deep vein thrombosis or DVT. These blood clots form in veins deep within the body, usually the... (Source: NaturalNews.com)
Source: NaturalNews.com - August 23, 2018 Category: Consumer Health News Source Type: news

Access Vascular raises $3m for anti-clot PICC technology
Access Vascular raised more than $3 million from a consortium of new and existing investors that CEO Jim Biggins said should be sufficient to carry the company through a post-market clinical evaluation of its HyrdoPICC catheter and into the regulatory process for its next iteration. Biggins told MassDevice.com yesterday that the $3.4 million round was led by a “family office in the Boston area” that’s backed Access since its 2015 inception. “They’ve been supporting us since the beginning of the company and they helped price and lead this most recent round,” he told us, adding t...
Source: Mass Device - August 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Funding Roundup Vascular Wall Street Beat accessvascular Source Type: news